RxDoctor Payments Data

David Hill, MD

Plastic Surgery · Alpharetta, GANPI 1649614132

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,042 of the $9,524 with a category attached, or 63.4%. 20 manufacturers reported payments, led by AbbVie at 56.0% of the total. Reporting peaked in 2021 at $5,064 and has fallen 87.9% since, to $612 in 2025.

$9,524in general payments, 2019–2025

Across 106 payments — averaging $89.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Merz North America, Inc.$920
  • Medical Device Business Services, Inc.$740
  • Axogen$645
  • Integra Lifesciences Corporation$298
  • Medline Industries LP$285
  • plus $1K from 14 others
$222,886in research payments, 2019–2025

Across 13 payments — averaging $17,145 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merz North America, Inc.$223K
  • Davol Inc.$342

What the payments were for

  • Consulting fees$1,47515%
  • Travel & lodging$1,31714%
  • Food & beverage$6,04263%
  • Education$6907%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,524 in reported general payments places this provider in the 80th percentile of 163 plastic surgery providers in Georgia.

See all plastic surgery providers in Georgia

Medicare billing

Part B allowed, 2024
$23,230
Medicare patients
21
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cephalexin44$985
Celecoxib22$320
Gabapentin35$174
Oxycodone Hcl25$72
Promethazine Hcl11$28

Paid to pharmacies, not to this prescriber.

Other plastic surgery in Alpharetta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →